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Nuclear factor-kappa B (NF-κB) activation is a key early signal regulating inflammatory
and cell death responses in acute pancreatitis. Our previous in vitro studies withmolecular
approaches on AR42J cell showed that protein kinase D (PKD/PKD1) activation was
required in NF-κB activation induced by cholecystokinin 8 (CCK) or carbachol (CCh) in
pancreatic acinar cells. Recently developed small molecule PKD inhibitors, CID755673
and CRT0066101, provide potentially important pharmacological approaches to further
investigate the effect of PKD in pancreatitis therapy. The aim of this study was to explore
whether CID755673 and CRT0066101 block NF-κB activation with in vitro and in vivo
models of experimental pancreatitis and whether the small molecule PKD inhibitors have
therapeutic effects when given before or after the initiation of experimental pancreatitis.
Freshly prepared pancreatic acini were incubated with CID755673 or CRT006101,
followed by hyperstimulation with CCK or CCh. For in vivo experimental pancreatitis,
rats were treated with intraperitoneal injection of CID755673 or CRT0066101 prior to or
after administering cerulein or saline. PKD activation and NF-κB-DNA binding activity
in nuclear extracts from pancreatic acini and tissue were measured. The effects of
PKD inhibitors on pancreatitis responses were evaluated. Our results showed that both
CID755673 or CRT0066101 selectively and specifically inhibited PKD without effects on
related protein kinase Cs. Inhibition of PKD resulted in significantly attenuation of NF-κB
activation in both in vitro and in vivomodels of experimental pancreatitis. NF-κB inhibition
by CID755673 was associated with decreased inflammatory responses and attenuated
severity of the disease, which were indicated by less inflammatory cell infiltration, reduced
pancreatic interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1),
decreased intrapancreatic trypsin activation, and alleviation in pancreatic necrosis,
edema and vacuolization. Furthermore, PKD inhibitor CID755673, given after the initiation
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of pancreatitis in experimental rat model, significantly attenuated the severity of acute
pancreatitis. Therapies for acute pancreatitis are limited. Our results indicate that
small chemical PKD inhibitors have significant potential as therapeutic interventions by
suppressing NF-κB activation.
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INTRODUCTION
Acute pancreatitis is a disorder with pathologic features of
inflammation and necrosis in pancreatic tissue. Increasing
evidence has demonstrated that inflammatory response plays
a pivotal role in the development of the disease (Grady
et al., 1997; Frossard et al., 1999; Bhatia et al., 2000;
Gukovskaya et al., 2002; Pandol, 2006; Pandol and Raraty,
2007). The nuclear transcription factor NF-κB, a key signal
triggered during pancreatitis, regulates the expression of
pro-inflammatory cytokines, chemokines, immune receptors,
and other inflammatory molecules (Gukovsky et al., 1998;
Frossard et al., 1999; Tak and Firestein, 2001; Vaquero
et al., 2001), which are responsible for the severe systemic
inflammatory complications of the disease (Grady et al.,
1997; Frossard et al., 1999; Satoh et al., 1999; Bhatia et al.,
2000; Vaquero et al., 2001; Chen et al., 2002). Multiple
experimental models of pancreatitis have shown that NF-κB
activation in acinar cells is one of earliest events in acute
pancreatitis and the inhibition of NF-κB activation alleviates
the severity of the disease (Gukovsky et al., 1998, 2003; Satoh
et al., 1999; Vaquero et al., 2001). Further, NF-κB activation
within pancreas directly triggered by adenovirus-mediated gene
transfer can initialize pancreatic and systemic inflammatory
responses (Chen et al., 2002). Therefore, development of
pharmacological interventions to suppress NF-κB activation is
necessary to prevent severe pancreatitis in early stage of the
disease.
Serine/threonine protein kinase D (PKD) family, composed
of PKD/PKD1, PKD2, and PKD3, has recently characterized
as an important target in the signaling cascades initiated and
transduced through G protein coupled receptors, phospholipase
C, second messengers, and PKC-dependent or -independent
mechanisms in various cell types including pancreatic acinar
cells (Rozengurt et al., 2005; Berna et al., 2007; Yuan et al.,
2008; Chen et al., 2009; Rozengurt, 2011). PKD family members
have been implicated in the regulation of numerous cell
biological functions, such as Golgi complex integrity and protein
secretion (Rozengurt et al., 2005; Fugmann et al., 2007; Li
et al., 2008; Rozengurt, 2011), phosphorylation of heat shock
protein (Yuan and Rozengurt, 2008) and histone deacetylase
(Matthews et al., 2006; Sinnett-Smith et al., 2014), cell apoptosis
(Trauzold et al., 2003), and proliferation (Rozengurt et al.,
2005), oxidative stress and inflammation, heart diseases and
malignant tumors (Storz et al., 2004a; Chiu et al., 2007; Fielitz
et al., 2008; Sharlow et al., 2008; Harikumar et al., 2010).
Recent studies has revealed that PKDs are key transcriptional
regulators through induction of nuclear transcription factors
c-jun (Hurd et al., 2002), the cAMP-response element-binding
protein (Johannessen et al., 2007), and particularly, NF-κB (Storz
et al., 2004a,b).
PKDs can be activated by a numbers of gastrointestinal
secretagogues in pancreatic acini (Berna et al., 2007; Yuan
et al., 2008, 2012; Chen et al., 2009; Thrower et al., 2011;
Yuan and Pandol, 2016). Our studies showed that the peptide
hormone cholecystokinin 8 (CCK) and the cholinergic agonist
carbachol (CCh) induced a dose-dependent rapid activation
of PKD in pancreatic acini, which was closely correlated with
increased NF-κB activity (Yuan et al., 2008). With a molecular
approach to up- or down-regulate PKD expression in AR42J
acinar cell line, we showed that PKD mediated NF-κB activation
caused by CCK or CCh in pancreatic acinar cells (Yuan et al.,
2008).
CRT0066101 and CID755673, two small molecule chemicals,
have been newly identified as PKD specific inhibitors. Two
research groups have reported the in vitro and in vivo anti-
tumor growth effect of the inhibitors in pancreatic ductal
adenocarcinoma and prostate cancer respectively (Sharlow
et al., 2008; Harikumar et al., 2010). Of significant importance
for pancreatitis, we have reported that CRT0066101 reduces
secretagogues-induced zymogen premature activation in primary
pancreatic acini (Thrower et al., 2011) and that CID755673
treatment attenuates pancreatic necrotic death in cerulein-
induced experimental pancreatitis models (Yuan et al., 2012;
Yuan and Pandol, 2016). The aims of the current study are
to explore (1) whether the novel PKD inhibitors block NF-
κB activation in experimental pancreatitis models, and (2)
whether suppressing of NF-κB activation by the PKD inhibitors
is associated with attenuation of inflammatory response and
severity of pancreatitis, as well as (3) the therapeutic benefit
of the PKD inhibitors administered after induction of the
pancreatitis.
Our results identified PKD as a novel early signaling
triggered through CCK or cholinergic receptor to mediate NF-
κB activation in acute pancreatitis and demonstrated that PKD
inhibitors potently blocked NF-κB activation in in vitro and
in vivo experimental pancreatitis models. Importantly, NF-κB
inhibition by the PKD inhibitor CID755673 was associated with
significantly decreased inflammatory responses and alleviated
pancreatic histopathologic changes in pancreatitis. The beneficial
effects in pancreatitis were present both when the PKD
inhibitor was given before initiation of pancreatitis and during
pancreatitis.
Our studies indicate that the small chemical PKD suppressors
possess significant potential as therapeutic intervention to
alleviate/prevent serious pancreatitis at early stage of the disease
or to prevent recurrent pancreatitis through suppressing NF-κB
activation.
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MATERIALS AND METHODS
Reagents
CCK was from American Peptide (Sunnyvale, CA); Medium
199 was from GIBCO (Grand Island, NY). ATP and [γ-32P]
ATP were from Perkin Elmer (Torrance, CA). CRT0066101
and CID755673 were obtained from TOCRIS (Mo, USA).
Nitrocellulose membranes were from Schleicher and Schuell
BioSience. Carbachol and GF1 (also known as GF109203X
or bisindolylmaleimide I) were from Calbiochem (La Jolla,
CA). Antibodies against PKD C-20, IκB-α, or LDH were from
Santa Cruz Biotechnology (Santa Cruz, CA). Phosphoserine
744/748 PKD antibody that detects primarily the phosphorylated
state of Ser 744 (Jacamo et al., 2008), phosphoserine 916
PKD antibody, antibodies for NF-κB P65, phosphoserine
32/36 IκB-α, GAPDH, ERK1/2 were obtained from Cell
Signaling Technology (Beverly, MA). IL-6 antibody was from
PeproTech (Rocky Hill, NJ) and MCP-1 antibody was from
Antibodies-Online Inc. (Secaucus, NJ). Protein-A-agarose was
from Roche Applied Science (Mannheim, Germany) and
PKD substrate syntide-2, was from Bachem (Chicago, IL).
Other items were from standard suppliers or as indicated in
text.
Animals
Male Sprague-Dawley rats were used in all experiments. The
animals were kept in a temperature-(23 ± 2◦C) and humidity-
(55± 5%) controlled room with a 12-h light/dark cycle (lights on
at 07:00 a.m.). The animals were provided ad libitum standard rat
chow and tap water.
Animal Care Guidelines
Animal care and all procedures were approved by the
Institutional Animal Care and Use Committees of the Veterans
Affairs Greater Los Angeles Health Care System and Cedars-Sinai
Medical Center, Los Angeles in accordance with the National
Institutes of Health guidelines USA. Rats were kept under specific
pathogen-free conditions and received humane care according to
the guidelines of our institution. All experiments were performed
according to the guidelines of the National Institutes of Health
guidelines.
Preparation and Treatments of Dispersed
Pancreatic Acini and Preparation of Cell
Lysate
Pancreatic acinar cells were prepared frommale Sprague-Dawley
rats (75–100 g) using a collagenase digestion method as described
previously (Gukovsky et al., 1998; Yuan et al., 2008) and then
incubated in medium 199 supplemented with 0.01% trypsin
inhibitor (w/v), penicillin (100 U/ml), and streptomycin (0.1
mg/ml) at 37◦C in a 5% CO2-humidified atmosphere. For
experimental purposes, the acinar cells were pre-incubated in
the medium 199 for 2 h at 37◦C with or without inhibitors
as described previously (36) and then treated further with or
without agonists. Acinar cells were collected and washed with
PBS. Aliquots of the acinar cells were lysed and sonicated in
lysis buffer as described previously (Satoh et al., 2004). After
centrifugation at 15,000 × g for 10min at 4◦C, the protein
concentration in supernatants was measured using the Bio-Rad
protein assay reagent.
Experimental Pancreatitis and Pancreatic
Tissue Lysate Preparation
Sprague-Dawley rats (male, 120–150 g) were pre-treated with
intraperitoneal (IP) injection of PKD inhibitor CID755673 (CID,
15 mg/kg) or CRT0066101 (CRT, 10 mg/kg) 60min prior to
initiation of pancreatic stress with up to 4 hourly IP injections
of cerulein (20 µg/kg), a CCK analog used for experimental
pancreatitis models. Control animals received similar injections
of physiologic saline. We choose the dosages of the PKD
inhibitors in the animal experiments based on our previous dose
response (Yuan et al., 2012). Then the animals were sacrificed in
30min after first IP injection of cerulein or in 60min after 4th
hourly IP injection of cerulein. Blood samples and the pancreas
were obtained and stored at −80◦C for measurements. Portions
of frozen tissue were homogenized on ice in lysis buffer as
described previously (Satoh et al., 2004). After sonication the
lysates were rotated for 40min at 4◦C and centrifuged at 4◦C for
15min at 16,000 g. The supernatants were collected and stored
at−80◦C.
To determine potential of PKD inhibitor as therapeutics
after the disease has commenced, we induced rat pancreatitis
by 6 hourly cerulein injections. CID755673 (15 mg/kg)
or vehicle was administered by IP injection to rats at
early and late stages after the initiation of pancreatitis (i.e.,
30min after 1st and 4th of IP injection of cerulein). The
animals were sacrificed in 1 h after the 6 hourly cerulein
injections.
Preparation of Nuclear Extracts and NF-κB
DNA Binding Activity Measurement
Nuclear protein extracts were prepared using ActiveMotif
Nuclear Extract Kit (Carlsbad, CA) following the manufactory
instructions. NF-κB DNA binding activities were measured with
electrophoretic mobility shift assay (EMSA) as described in
our laboratory previously (Gukovsky et al., 1998; Yuan et al.,
2008).
Western Blot Analysis, PKD
Immunoprecipitation, and in Vitro Kinase
Assay
Western blot analyses were performed as described previously
(Yuan et al., 2003, 2008, 2012). The membranes were blocked
by 1–2 h incubation with 5% non-fat dried milk in Tris-
buffered saline, pH 7.2 and probed overnight at 4◦C with
specific primary antibodies at a 1:500–1:1,000 dilution in the
Tris-buffered saline containing 3% non-fat dried milk. Then
the membranes were incubated with secondary antibodies
conjugated with horseradish peroxidase at 1:5,000 dilutions for
1 h at room temperature. Blots were developed by using the
enhanced chemiluminescence detection kit (Pierce). When re-
probing was necessary, the membrane was stripped of bound
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antibody by incubating in Re-Blot Plus Mild Solution (Millipore,
Temecula, CA) for 20min.
PKD in pancreatic tissue lysates was immunoprecipitated at
4◦C for 3 h with the PKD C-20 antibody (1:100) and protein-
A-agarose as previously described (Yuan et al., 2002, 2003,
2008, 2012). Exogenous substrate syntide-2 phosphorylation by
immunoprecipitated PKD was carried out by mixing 20 µl of
the washed immunocomplexes with 10 µl of a phosphorylation
mixture containing 100µM ATP (including [γ-32P]ATP at 2
µCi/assay or with specific activity, 400–600 cpm/pmol) and 2.5
mg/ml syntide-2 (PLARTLSVAGLPGKK) in kinase buffer. After
10min of incubation at 30◦C, the reaction was stopped by adding
100 µl of 75mM H3PO4, and 75 µl of the supernatant was
spotted on P-81 phosphocellulose paper. Free [γ-32P]ATP was
separated from the labeled substrate by washing the P-81 paper
four times for 5min in 75mM H3PO4. The papers were dried,
and the radioactivity incorporated into syntide-2 was determined
by Cerenkov counting.
Enzymatic Assays
Animal serum amylase and lipase activities were determined by
Antech Diagnostics (Irvine, CA) Custom Service. Active trypsin
in pancreatic tissue was measured by using Boc-Gln-Ala-Arg-
AMC as a substrate by a fluorescent assay as described previously
(Gukovskaya et al., 2002).
Quantification of Necrosis
Quantification of necrosis in in vivo pancreatitis was performed
on pancreatic tissue (collected after 4 or 6 hourly cerulein
injections) sections stained with H&E as described previously
(Mareninova et al., 2006; Sung et al., 2009; Yuan et al., 2012). Cells
with swollen cytoplasm, loss of plasma membrane integrity, and
leakage of organelles into interstitium were considered necrotic.
A total of at least 2,000 acinar cells were counted on tissue
sections from each animal and 3–5 animals per condition were
counted.
Histologic Analysis for Pancreas
Inflammatory Cell Infiltration and
Vacuolization and Measurement of Edema
Quantification of inflammatory cell infiltration and vacuolization
was performed on H&E stained pancreatic tissue (4–6 hourly
cerulein injections) sections from at least 4 mice per group
and expressed as the number of inflammatory cells or vacuoles
per 100 acinar cells. Pancreatic edema grading was made on
the H&E stained tissue sections from 0 to 3 according to the
Schoenberg grading system (Schoenberg et al., 1990): 0: no
edema; 1: interlobular edema; 2: moderate interlobular and
intra-acinar edema; and 3: severe interlobular and intra-acinar
edema.
Statistical Analysis
Results were expressed as the mean ± SD of at least three
independent experiments. The experimental data was
evaluated by the analysis of variance (ANOVA) followed
by Bonferroni multiple comparison post-hoc tests with
the GraphPad Prism software (GraphPad Software Inc. La
Jolla, California). T-tests were used to analyze differences
between two groups. P <0.05 was considered statistically
significant.
RESULTS
CID755673 and CRT0066101 Inhibit Both
PKD Activation and NF-κB Activation in
in Vitro Model of Pancreatitis Induced by a
High Dose of CCK or CCh Stimulation
We previously showed that CRT0066101 reduced secretagogues-
induced PKD activation (Thrower et al., 2011) and that
CID755673 inhibited CCK-induced PKD activation (Yuan et al.,
2012) in primary pancreatic acinar cells. Here, in a consistent
experiment, we examined the effect of both inhibitors on PKD
activation induced by CCK and CCh (Figure 1). Pancreatic acini
freshly prepared from rat were incubated with 25µMCID755673
or 10µM CRT0066101 for 2 h followed by challenging with
a high dose of the pancreatic secretagogues CCK (100 nM)
or CCh (200µM) which were known to induce pancreatitis
pathologies in acini in vitro (Gukovsky et al., 2003; Yuan
et al., 2008, 2012; Thrower et al., 2011). Our results showed
that both CCK and CCh dramatically induced PKD activation
determined by Western blot to measure autophosphorylation of
PKD/PKD1 Ser916. The PKD activation was potently inhibited
by pre-incubation with either CID755673 or CRT0066101. Both
inhibitors did not affect PKD phosphorylation at its activation
loop (Ser744/748) (Figure 1A) which was known largely via
PKC-dependent pathways in pancreatic acinar cells (Berna et al.,
2007; Yuan et al., 2008), but the Ser744/748 phosphorylation
was almost abolished by Go6983 (10µM), a conventional and
novel PKC inhibitor (Figure 1A). The results indicate that
CID755673 and CRT0066101 directly affect PKD activation
independent of upstream pathways known to mediate PKD
activation.
Next, to determine the effect of the PKD inhibitors
on CCK- or CCh-induced NF-κB activation, we prepare
nuclear extracts using the acini collected in the same
experiments described above. NF-κB-DNA binding activity
in the nuclear extracts was measured by EMSA. Either
CID755673 or CRT0066101 significantly decreased NF-
κB activation induced by CCK or CCh (Figures 1B,C).
Inhibition of NF-κB was corresponding to the inhibition of
PKD. These results are consistent with our previous findings
achieved in AR42J cell line by using molecular approaches
to upregulate or downregulate PKD expression (Yuan et al.,
2008).
It has been known that NF-κB is present in the cytoplasm
as an inactive state by association with the inhibitory (IκB)
proteins. Upon activation, the inhibition of NF-κB by IκBs is
removed as soon as IκBs are phosphorylated by IKK kinases
and the phosphorylated IκBs rapidly degrade via proteasome-
involving pathways. Active NF-κB will redistribute into the
nucleus and promote the expression of a number of genes
that contain κB-binding sites in their promoters/enhancers
(Gukovsky et al., 2003). We here found that PKD activation
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plays an important role in these events preceding NF-
κB activation. Corresponding to PKD inhibition, both IκB-
α phosphorylation and degradation caused by CCK- and
CCh stimulation were decreased in the cells pre-treated
with CID755673 or CRT0066101 (Figure 2A). Further, our
Western blot analysis of cell cytosol NF-κB level also showed
that either CID755673 or CRT0066101 inhibited nuclear
translocation of NF-κB in acinar cells (Figure 2B). The
inhibitory effect of the two small compounds on either IκB-α
phosphorylation/degradation or nuclear translocation of NF-κB
was in accordance with their inhibitory effects on NF-κB-DNA
binding activity (Figures 1B,C).
PKD Inhibitors CID755673 and CRT0066101
Suppress NF-κB Activation in in Vivo
Experimental Model of Pancreatitis
Induced by Cerulein
To determine whether the two small molecule PKD inhibitors
blocked NF-κB activation in the CCK analog cerulein-induced
animal model of pancreatitis, we first tested their in vivo
selectivity and specificity for PKD when the inhibitors were
administered to animals. Rats were IP injected with CID755673
(15 mg/kg) or CRT0066101 (10 mg/kg) and the control rats
received the same volume of vehicle (DMSO). Sixty minutes later,
cerulein (dissolved in saline) or saline only were administered
to the inhibitor- or vehicle-pretreated animals. Thirty minutes
after the cerulein injection, we harvested the pancreas and
measured pancreatic PKD/PKD1 catalytic activity with in vitro
kinase assays. As showed in Figure 3A, as high as 60–70%
of PKD activation induced by cerulein was inhibited in the
animals pretreated with CID755673 or CRT0066101. Similar
to the in vitro experimental results shown above, the two
inhibitors also suppressed PKD Ser916 autophosphorylation
(Figure 3B) but had no effect on PKD/PKD1 Ser744/748
phosphorylation which was majorly through PKC-dependent
pathways in pancreatitis (Figure 3B), confirming the selectivity
and specificity of CID755673 and CRT0066101 targeting PKD
in vivo.
We then investigated whether the inhibition of PKD
activation by the two small molecule chemicals has effect on
NF-κB activation in cerulein pancreatitis animal model. The
nuclear extracts prepared from the rat pancreatic tissue were
used in EMSA measurement for NF-κB DNA binding activity.
Figures 4A,B show that control (saline) rats, treated either
without or with either inhibitor, had no or very low NF-κB
activity. Cerulein hyperstimulation induced a striking increase
in NF-kB activation, which was greatly attenuated (by ∼60–
70% as quantification in the bar figures of Figure 4) in either
CID755673-treated or CRT0066101-treated rats (P < 0.01 or P
< 0.05). The combined results in Figures 3,4 indicate that the
inhibition of NF-κB activation by the two inhibitors was closely
correlated to their inhibition to PKD activation. Moreover, our
Western blot analysis of pancreatic cytosol IκB-α and NF-
κB levels showed that CID755673 inhibited degradation of
IκB-α and nuclear distribution of NF-κB in cerulein-induced
FIGURE 1 | Small molecule chemicals CID755673 and CRT0066101 inhibit
high dose secretagogue-induced PKD activation and NF-κB activation in
pancreatic acinar cells. Rat pancreatic acinar cells were incubated with or
without CID755673 (CID, 25µM) or CRT0066101 (CRT, 10µM) and PKC
inhibitor Go6983 (10µM) for 2 h prior to 100 nM CCK or 200µM CCh
treatment for an additional 30min. (A) Western blot was performed to analyze
PKD phosphorylation in cell lysate. PKD and ERK1/2: for loading controls.
(B) NF-κB-DNA binding activity was measured in cell nuclear extracts (NE) by
EMSA. (C) NF-κB band intensities were quantified in the PhosphorImager and
normalized on the band intensity in unstimulated control acini. Values are
means ± SE (n = 3). *p < 0.05 vs. CCK or CCh (#) alone without inhibitor
pre-treatments.
pancreatitis (Figure 4C). The results were consistent with the
inhibitory effect of CID755673 on NF-κB activity (Figure 4A).
NF-κB Inhibition by PKD Inhibitor
CID755673 Was Associated with
Decreased Pancreatic Levels of
Inflammatory Molecules IL-6 and MCP-1
To test whether the inhibition of NF-κB by the PKD inhibitor
altered expression of inflammatory molecules in pancreatitis,
we examined pancreatic level of cytokine IL-6 and chemokine
MCP-1. As shown in Figure 5, both IL-6 and MCP-1 levels
were very low within the normal pancreas, whereas cerulein
induced significantly increased IL-6 and MCP-1 in pancreatitis.
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FIGURE 2 | PKD inhibitors decrease secretagogue-induced IkB-α
phosphorylation and degradation and nuclear translocation of NF-κB. Rat
pancreatic acinar cells were incubated with or without CID (25µM) or CRT
(10µM) for 2 h prior to 100 nM CCK or 200µM CCh treatment for an
additional 30min. (A) IκB-α phosphorylation and degradation were measured
in cell cytosolic extract by Western blot. ERK1/2: for loading control. The
Western blot results of IκB-α phosphorylation and degradation was quantified
and expressed as the ratio of pS IκB-α to IκB-α in the bar figures. (B) Western
blot analysis of NF-κB P65 in cell cytosolic extract. LDH: for cytosolic extract
loading control. The results were representative of two independent
experiments.
CID755673 treatment markedly inhibited pancreatic expression
of IL-6 and MCP-1 in cerulein-induced pancreatitis (Figure 5).
NF-κB Inhibition by PKD Inhibitor
CID755673 Was Associated with
Significantly Alleviated Severity of
Pancreatitis
Subsequently, we evaluated the effect of NF-κB inhibition by
the PKD inhibitor CID755673 on the pathologic changes in
pancreatitis. Following 1 h injection of CID755673 (15 mg/kg),
we gave the rats up to 4 hourly IP injections of cerulein (20µg/kg)
and the control rats received saline IP injections. The rats were
then sacrificed at 30min and 4 h after the first cerulein injection.
The results in Figure 6A showed that strikingly increased
blood amylase and lipase and intrapancreatic trypsin activation in
pancreatitis were significantly decreased in rats with CID755673
pretreatment. CID755673 markedly alleviated the histological
injuries in cerulein pancreatitis (Figure 6B). Cerulein-induced
interstitial edema was prevented by CID755673 treatment as
FIGURE 3 | CID755673 or CRT 0066101 pretreatment inhibits PKD activation
in cerulein-induced experimental pancreatitis. Rats received intraperitoneal (IP)
injection of CID755673 (CID, 15 mg/kg) or CRT 0066101 (CRT, 10 mg/kg).
Control rats received same volume of vehicle DMSO. After 60min waiting time,
the inhibitor- or vehicle-pretreated animals were given an IP injection of
cerulean (CR) or saline (S). The pancreas was collected in 30min after the
cerulein or saline injection. (A) The pancreas tissue lysates were
immunoprecipitated with PKD/PKD1 C-20 antibody and PKD1 activity in the
immunocomplexes was determined by in vitro kinase assay (IVK). PKD/PKD1
catalytic activities were expressed increased fold over control in the animals
injected with saline. Results are means ± SE (n = 3–5) for each condition.
**p < 0.01 vs. cerulein alone without inhibitor pre-treatments. (B) Western blot
was performed to analyze PKD phosphorylation in the tissue lysates using
antibodies against phospho-Ser916 PKD, phospho-Ser744/748 PKD. PKD
and GAPDH or ERK1/2: for loading controls. Samples were run in a single gel
but were not continuous, as indicated by a line between lanes.
early as 30min after 1st injection of cerulein (Figures 6B,C).
Furthermore, the major pancreas histological changes in animals
pretreated with CID755673 are the strikingly attenuation
of inflammatory cell infiltration and acinar cell necrosis
in pancreatitis (Figures 6D,E). Accumulation of cytoplasmic
vacuoles was also significantly reduced in CID755673-treated
rats (Figure 6F). These results achieved from the in vivo animal
model of pancreatitis indicated that NF-κB inhibition by the PKD
inhibitor CID755673 was associated with significantly decreased
severity of acute pancreatitis.
Therapeutic Benefits of Novel Small
Molecule PKD Inhibitor in Rodent
Experimental Pancreatitis
To determine potential of PKD inhibitors as therapeutics after
the disease has commenced, we administered CID755673 (15
mg/kg) or vehicle by intraperitoneal (IP) injection to rats in
early and late stages after the initiation of pancreatitis (i.e.,
30min after 1st and 4th of IP injection of cerulein). The
animals were sacrificed in 1 h after the 6th hourly cerulein
injections and the pancreas were collected. We found that
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FIGURE 4 | PKD inhibitor CID755673 or CRT 0066101 pretreatment
attenuates NF-κB activation in cerulein-induce experimental pancreatitis. Rats
received intraperitoneal (IP) injection of CID755673 (CID, 15 mg/kg) or CRT
0066101 (CRT, 10 mg/kg) or same volume of vehicle. After 60min waiting
time, the inhibitor- or vehicle-pretreated animals were given an IP injection of
cerulean (CR) or saline (S). The pancreas was collected in 30min after the
cerulein or saline injection. (A,B) NF-κB binding activity was measured in
pancreatic tissue nuclear extracts by EMSA. Each lane represents one rat.
**p < 0.01 or *p < 0.05 vs. cerulein alone without inhibitor pre-treatments.
(C) IκB-α degradation and nuclear translocation of NF-κB were measured in
pancreatic tissue cytosolic extract by Western blot. LDH: for cytosolic extract
loading control. Samples were run in a single gel but were not continuous, as
indicated by a line between lanes.
blood amylase and lipase dramatically elevated after 6 hourly
IP injections of cerulein (Figure 7A), but, both enzymes were
markedly decreased in CID755673-treated rats although the
change of lipase did not have statistical significance (P =
0.054) between CID755673-treated and the control groups
(Figure 7A). Histology staining of the pancreatic tissue indicated
that treatment of CID755673 obviously improved pancreatic
histopathology (Figure 7B). Compared to vehicle-treated rats,
there was 50–60% reduction of pancreatic edema (Figure 7C),
inflammatory cell infiltration (Figure 7D), necrosis (Figure 7E),
and vacuole accumulation (Figure 7F) in CID755673-treated
rodents after 6 hourly cerulein injections.
DISCUSSION
Acute pancreatitis is a serious medical disorder and at present,
there are no treatments targeting its molecular pathogenesis. The
FIGURE 5 | CID755673 (CID) pretreatment decreases pancreatic levels of IL-6
and MCP-1 in cerulein (CR)-induce pancreatitis. Western blot was performed
to analyze pancreatic levels of IL-6 and MCP-1 in the tissue lysates using
antibody against rat IL-6 (A) or MCP-1 (B). ERK1/2: for loading controls. The
Western blot band intensities were quantified and normalized by the loading
controls and expressed as the ratio over the untreated control in the bar
figures. Bar values are means ± SE, *p < 0.05 vs. rats without CID treatments
in CR-induced pancreatitis. (A,B) Samples were run in a single gel but were
not continuous, as indicated by a line between lanes.
transcription factor NF-κB has been known as an important
regulator of the production of the inflammatory molecules
and plays a critical role in the inflammatory response and
parenchymal injury in pancreatitis (Gukovsky et al., 1998, 2003;
Frossard et al., 1999; Satoh et al., 1999; Tak and Firestein, 2001;
Vaquero et al., 2001; Chen et al., 2002). NF-κB activation is
an early event in experimental pancreatitis, thus blocking the
upstream signaling pathways mediating NF-κB activation in
pancreatitis will be important for early treatment of this serious
disease.
Our previous studies with molecular approach in AR42J
cell line showed that PKD was required in NF-κB activation
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FIGURE 6 | CID755673 (CID) pretreatment attenuates inflammation, necrosis, and severity in cerulein-induced pancreatitis. Rats received IP injection of CID followed
by up to 4 hourly IP injections of cerulein (CR) or saline (S), as described in Methods. (A) Blood amylase and lipase activation and intrapancreatic trypsin activation (in
30min after 1st IP injection of CR) in pancreatitis were decreased in CID755673-treated rats. (B) H&E stained sections of pancreatic tissue. Edema in early stage
(30min) and late stage (4 h) (C) and the percentage of inflammatory cell infiltration (D), necrosis (E), and number of vacuoles (F) were measured on H&E stained
sections. Values are means ± SE (n > 4). *p < 0.05 or **p < 0.01 vs. CR alone without inhibitor pre-treatments.
in in vitro model of pancreatitis induced by CCK and the
cholinergic agonist CCh (Yuan et al., 2008), it is therefore
of significance to further investigate the function of PKD
in NF-κB activation with in vivo experimental models of
pancreatitis. Recent development of novel small molecule
chemical PKD inhibitors brings us a useful pharmacological
approach to achieve this goal. We report here that PKD
is a critical regulator of NF-κB activation in experimental
models of pancreatitis. Either in vitro or in vivo application
of the two PKD inhibitors, CID755673 and CRT0066101,
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FIGURE 7 | CID755673 post-treatment ameliorated the severity of pancreatitis. (A) Blood amylase and lipase activation was decreased in cerulein-induced rat
pancreatitis treated with PKD inhibitor CID755673 (CID, 15 mg/kg). (B) Representative H&E-stained pancreatic sections from rat pancreatitis treated without or with
CID 755673 compound. Compared to rats without CID755673 treatment, cerulein (CR) induced pancreatitis was greatly ameliorated in rats treated with CID755673
(CID). Edema (C) and the percentage of inflammatory cell infiltration (D) necrosis (E) and number of vacuoles (F) were measured on H&E stained sections. Values are
means ± SE (n > 3). *p < 0.05, **p < 0.01, or #p = 0.054 vs. CR alone without inhibitor pre-treatments.
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significantly prevented NF-κB activation in early stage of
pancreatitis.
We first showed that either CID755673 or CRT0066101
was a specific PKD inhibitor that potently blocked agonist-
induced PKD autophosphorylation at Ser916 without affecting
PKC-dependent Ser744/748 phosphorylation (that was inhibited
by PKC inhibitor Go6983, Figure 1). More important finding
was that PKD inhibition resulted in markedly suppressed NF-
κB-DNA binding activity in nuclear extracts from the acini
pretreated with CID755673 or CRT0066101 (Figure 1). The
results confirm the requirement of PKD in NF-κB activation
previously reported by our studies on AR42J cells with a
molecular approach (Yuan et al., 2008).
It has been known that NF-κB activation takes place when
the inhibitory IκB protein is degraded and dissociated with the
NF-κB complex. Activated NF-κB then redistributes to nucleus
and promotes the expression of a number of genes that contain
κB-binding sites in their promoters (Gukovsky et al., 2003; Yuan
et al., 2008). We examined the effect of the two PKD inhibitors
on IκB-α protein and NF-κB nuclear translocation. CCK or CCh
hyperstimulation caused IκB-α phosphorylation/degradation
and nuclear translocation of NF-κB in the pancreatic acini
(Figure 2). These events were potently inhibited by treatment
of either CID755673 or CRT0066101, whereas the inhibitor
did not change IκB-α and cytosol NF-κB amount in control
cells (Figure 2). These results indicate that the PKD inhibitors
attenuate pancreatic NF-κB activation and subsequent nuclear
translocation by preventing the phosphorylation and degradation
of IκB protein. PKD has been reported to mediate NF-κB
activation at the level of the IKK complex in oxidative stress. PKD
could directly interact with IKK, leading to its activation (Storz
et al., 2004b). Our evidence presented here also suggests that PKD
mediates NF-κB activation through acting at targets upstream of
IκB degradation, probably through upstream of IKK kinases. The
detail mechanisms remain to be further illustrated.
Next, we employed CID755673 and CRT0066101 in animals
to study whether PKD inhibition affected NF-κB activation in
in vivo experimental model of pancreatitis. Consistent with our
in vitro experimental results, selective and specific inhibition
of PKD catalytic activity and Ser 916 autophosphoryltion by
either inhibitor (Figure 3) resulted in strikingly decreased NF-κB
activation in early stage of acute pancreatitis in rats pre-treated
with CID755673 or CRT0066101 compound (Figure 4).
We then explored whether suppressing NF-κB activation
by the PKD inhibitors was associated with attenuation of
inflammatory responses and severity of the disease in
experimental model of pancreatitis. We found that NF-κB
inhibition by CID755673 was associated with significantly
decreased inflammatory responses indicated by reduced
pancreatic IL-6 and MCP-1 proteins (Figure 5), less
inflammatory cell infiltration in pancreatic tissue sections,
and reduced pancreatic trypsin activation, necrosis, edema and
vacuolization (Figure 6).
Cytokines have multiple functions in regulating the
immunoinflammatory responses. In particular, IL-6 plays a
key role in the convert from neutrophils to macrophages
during the transformation from innate to acquired immunity
FIGURE 8 | A scheme summarizing the signaling pathway through which PKD
mediates NF-κB activation and the role of PKD in multiple pathological
processes associated with pancreatitis. Our previous studies identified PKD as
a convergent point for PKCδ and ε activation in the signal pathways initiated
through CCK or CCh G-protein receptors and mediated NF-κB activation in
pancreatic acinar cells (Yuan et al., 2008). Here with both in vitro and in vivo rat
pancreatitis models, we found that activated PKD regulates NF-κB activation
in CCK/cerulein-induced pancreatitis through promoting IκB protein
phosphorylation and degradation. Activation of NF-κB results in inflammation
and pancreatitis. Small molecule PKD inhibitors can block this pathobiologic
process. This scheme also summarized the role of PKD in multiple
pathological processes associated with pancreatitis. CCK/cerulein-induced
PKD activation promotes necrosis in pancreatitis by regulating multiple cell
death signaling proteins (Yuan et al., 2012); Active PKD also mediates amylase
secretion and zymogen activation through regulating cathepsin B (Thrower
et al., 2011). These pathologic responses can be blocked when PKD is
inhibited by small molecule PKD inhibitors, resulting in amelioration of the
severity of pancreatitis. All these effects indicate that PKD may represent a
potential therapeutic target in pancreatitis. See the text and references (Yuan
et al., 2008, 2012; Thrower et al., 2011) for details.
(Maianski et al., 2004; Jones, 2005; Gukovsky et al., 2008). Of
significance for pancreatitis is that a good correlation between
the level of IL-6 with the disease severity has been observed
in human pancreatitis (Bhatia et al., 2000). MCP-1 is a strong
chemoattractant for the recruitment of monocytes/macrophages
(Maianski et al., 2004; Jones, 2005; Gukovsky et al., 2008). During
pancreatitis, not only the inflammatory cells but also injured
acinar cells can produce MCP-1 (Blinman et al., 2000; Bhatia
et al., 2005; Gukovsky et al., 2008). Further evidence showed
that inhibition of MCP-1 resulted in amelioration of both
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acute cerulein pancreatitis (Bhatia et al., 2005) and the chronic
pancreatitis induced by dibutyltin dichloride (Zhao et al., 2005).
The transcription factor NF-κB has been known as a
major regulator of the inflammatory molecules expression in
pancreatitis. Both IL-6 and MCP-1 expression is under the
control of NF-κB because promoters of these genes have
DNA binding sites of NF-κB (Ben-Baruch et al., 1995; Marks-
Konczalik et al., 1998). In many inflammatory diseases including
pancreatitis, activated NF-κB translocates to neucleus and binds
to the gene promoters for proinflammatory cytokine IL-6
and monocyte chemoattractant MCP-1, resulting in increased
production of IL-6 and MCP-1 (Martin et al., 1999; Pandol
et al., 1999; Roebuck et al., 1999; Tak and Firestein, 2001;
Vaquero et al., 2001; Gukovsky et al., 2008). Therefore, we
here examined IL-6 or MCP-1 protein level in pancreatic tissue
lysates and found that NF-κB inhibition by PKD inhibitor
CID755673 was associated with significantly reduced pancreatic
production of IL-6 and MCP-1 proteins. The results suggest that
PKD inhibitor could suppress expression of the inflammatory
molecule IL-6 and MCP-1 through inhibiting NF-κB activation
in pancreatitis.
Previously, we investigated whether the PKD inhibitor
CRT0066101 would prevent zymogen activation in pancreatitis
in an in vitro pancreatitis model in rat pancreatic acinar
cells (Thrower et al., 2011). We found that secretagogue-
induced zymogen activation was markedly reduced by treatment
of the acini with the PKD inhibitor without affecting basal
zymogen activation or secretion. Particularly, trypsin activities
were all dramatically reduced in CCK-, CCh-, and bombesin-
stimulated cells which had been pretreated with the PKD
inhibitor CRT0066101. Further studies showed that CCK-
induced cathepsin B activity was inhibited by CRT0066101
(Thrower et al., 2011). These results indicated that the potential
mechanism by which PKD mediates zymogen activation was
through regulating cathepsin B, a lysosomal hydrolase that
has been known to play a role in intrapancreatic trypsinogen
activation and the onset of acute pancreatitis. Of significance,
we here demonstrated that PKD inhibitor also strongly inhibited
intrapancreatic trypsin activation and pancreatic vacuolization in
in vivo rat cerulein-induced pancreatitis, which supported our
previous in vitro experimental results, confirming again PKD
regulates zymogen activation in pancreatitis.
There was very little information regarding application of
the PKD inhibitors in therapy of pancreatitis in experimental
animal models. It is exciting that our final results achieved from
experiments in which the rats were treated by CID755673 after
the pancreatitis has commenced showed that the post-treatment
of the PKD inhibitor significantly attenuated pancreatic injury
in cerulein-induced pancreatitis (Figure 7). The studies further
confirmed that PKD is an important molecular target for therapy
of acute pancreatitis and suggest a high therapeutic potential of
the small molecule PKD inhibitors in this disorder.
In summary, our studies demonstrate that PKD is a key
mediator of NF-κB activation in in vivo model of pancreatitis.
Small chemical inhibitors of PKD have significant potential as
therapeutic intervention for pancreatitis through blocking NF-
κB activation, a critical early pathological event in this disease.
Combining with our previous reports (Yuan et al., 2008, 2012;
Thrower et al., 2011; Yuan and Pandol, 2016) that identified
PKD as an early convergent target of PKCδ and ε signaling
in NF-κB activation in exocrine pancreas, we summarized our
findings in Figure 8 to show the signaling pathways of PKD
mediating NF-κB activation in pancreatitis. In addition, we here
also presented/summarized the overall role of PKD, which we
found so far, in multiple pathological processes associated with
pancreatitis (Figure 8).
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